TY - JOUR
T1 - Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia
T2 - Outcomes from a large multi-center collaboration
AU - Stephens, Deborah M.
AU - Boucher, Ken
AU - Kander, Elizabeth
AU - Parikh, Sameer A.
AU - Parry, Erin M.
AU - Shadman, Mazyar
AU - Pagel, John M.
AU - Cooperrider, Jennifer
AU - Rhodes, Joanna
AU - Mato, Anthony
AU - Winter, Allison
AU - Hill, Brian
AU - Gaballa, Sameh
AU - Danilov, Alexey
AU - Phillips, Tycel
AU - Brander, Danielle M.
AU - Smith, Sonali M.
AU - Davids, Matthew S.
AU - Rogers, Kerry
AU - Glenn, Martha J.
AU - Byrd, John C.
N1 - Funding Information:
National Cancer Institute (R35 CA198183; K23 CA212271), Four Winds Foundation, Connie Brown CLL Fund, Kevin Sullivan Foundation, and the D. Warren Brown Foundation.
Publisher Copyright:
©2021 Ferrata Storti Foundation
PY - 2021/11
Y1 - 2021/11
N2 - Chronic lymphoma of care lymphocytic exists. (HL) We have conducted leukemia limited survival. (CLL) a multi-center patients No current who retrospective therapeutic develop study Hodgkin standard of patients with Hodgkin transformation (HT) of CLL. Clinicobiologic characteristics, treatment type, and survival outcomes were analyzed and compared with historic case series. Ninety-four patients were identified. Median age at HT was 67 years (range, 38-85). Median time from CLL diagnosis to HT was 5.5 years (range, 0-20.2). Prior to HT, patients received a median of two therapies for CLL (range, 0-12). As initial therapy for HT, 61% (n=62) received ABVD-based regimens (adriamycin, bleomycin, vinblastine, and dacarbazine). Seven (7%) patients received hematopoietic cell transplantation (HCT) while in first complete remission (CR1). The median number of treatments for HT per patient was one (range, 0-5) with 59 (61%) patients only receiving one line of therapy. After HT, patients had a median follow-up of 1.6 years (range, 0-15.1). Two-year overall survival (OS) after HT diagnosis was 72% (95% Confidence Interval: 62-83). The patients who received standard ABVD-based therapy had a median OS of 13.2 years. Although limited by small sample size, the patients who underwent HCT for HT in CR1 had a similar 2-year OS (n=7; 67%) compared to patients who did not undergo HCT for HT in CR1 (n=87; 72%; P=0.46). In this multi-center study, HT patients treated with ABVD-based regimens had prolonged survival supporting the use of these regimens as standard of care for these patients.
AB - Chronic lymphoma of care lymphocytic exists. (HL) We have conducted leukemia limited survival. (CLL) a multi-center patients No current who retrospective therapeutic develop study Hodgkin standard of patients with Hodgkin transformation (HT) of CLL. Clinicobiologic characteristics, treatment type, and survival outcomes were analyzed and compared with historic case series. Ninety-four patients were identified. Median age at HT was 67 years (range, 38-85). Median time from CLL diagnosis to HT was 5.5 years (range, 0-20.2). Prior to HT, patients received a median of two therapies for CLL (range, 0-12). As initial therapy for HT, 61% (n=62) received ABVD-based regimens (adriamycin, bleomycin, vinblastine, and dacarbazine). Seven (7%) patients received hematopoietic cell transplantation (HCT) while in first complete remission (CR1). The median number of treatments for HT per patient was one (range, 0-5) with 59 (61%) patients only receiving one line of therapy. After HT, patients had a median follow-up of 1.6 years (range, 0-15.1). Two-year overall survival (OS) after HT diagnosis was 72% (95% Confidence Interval: 62-83). The patients who received standard ABVD-based therapy had a median OS of 13.2 years. Although limited by small sample size, the patients who underwent HCT for HT in CR1 had a similar 2-year OS (n=7; 67%) compared to patients who did not undergo HCT for HT in CR1 (n=87; 72%; P=0.46). In this multi-center study, HT patients treated with ABVD-based regimens had prolonged survival supporting the use of these regimens as standard of care for these patients.
UR - http://www.scopus.com/inward/record.url?scp=85093538553&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85093538553&partnerID=8YFLogxK
U2 - 10.3324/haematol.2020.256388
DO - 10.3324/haematol.2020.256388
M3 - Article
C2 - 33054118
AN - SCOPUS:85093538553
VL - 106
SP - 2845
EP - 2852
JO - Haematologica
JF - Haematologica
SN - 0390-6078
IS - 11
ER -